{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:26:00Z","timestamp":1774448760402,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10067-018-4071-9","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T09:06:35Z","timestamp":1523610395000},"page":"1807-1816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial"],"prefix":"10.1007","volume":"37","author":[{"given":"Violetta","family":"Opoka-Winiarska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"\u017buber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Alexeeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vyacheslav","family":"Chasnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Nikishina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gra\u017cyna","family":"D\u0119bowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Smolewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"4071_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390\u2013392","journal-title":"J Rheumatol"},{"key":"4071_CR2","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/rheumatology\/kep144","volume":"48","author":"S Ringold","year":"2009","unstructured":"Ringold S, Seidel KD, Koepsell TD, Wallace CA (2009) Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 48:972\u2013977","journal-title":"Rheumatology (Oxford)"},{"key":"4071_CR3","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1002\/art.21389","volume":"52","author":"CA Wallace","year":"2005","unstructured":"Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH (2005) Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 52:3554\u20133562","journal-title":"Arthritis Rheum"},{"key":"4071_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/BOR.0000000000000206","volume":"27","author":"K Webb","year":"2015","unstructured":"Webb K, Wedderburn LR (2015) Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol 27:505\u2013510","journal-title":"Curr Opin Rheumatol"},{"key":"4071_CR5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A et al (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74:1110\u20131117","journal-title":"Ann Rheum Dis"},{"key":"4071_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/s10165-011-0481-0","volume":"22","author":"T Imagawa","year":"2012","unstructured":"Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H et al (2012) Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 22:109\u2013115","journal-title":"Mod Rheumatol"},{"key":"4071_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","volume":"18","author":"G Horneff","year":"2016","unstructured":"Horneff G, Klein A, Klotsche J et al (2016) Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther 18:272\u2013284","journal-title":"Arthritis Res Ther"},{"key":"4071_CR8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F Benedetti De","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385\u20132395","journal-title":"N Engl J Med"},{"key":"4071_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1517\/14712598.2016.1150997","volume":"16","author":"JL Turnier","year":"2016","unstructured":"Turnier JL, Brunner HI (2016) Tocilizumab for treating juvenile idiopathic arthritis. Expert Opin Biol Ther 16:559\u2013566","journal-title":"Expert Opin Biol Ther"},{"key":"4071_CR10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40:1202\u20131209","journal-title":"Arthritis Rheum"},{"key":"4071_CR11","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31:2290\u20132294","journal-title":"J Rheumatol"},{"key":"4071_CR12","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","volume":"74","author":"J Guzman","year":"2015","unstructured":"Guzman J, Oen K, Tucker LB et al (2015) The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 74:1854\u20131860","journal-title":"Ann Rheum Dis"},{"key":"4071_CR13","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/art.39626","volume":"68","author":"M Ghiti Moghadam","year":"2016","unstructured":"Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Dutch National POET Collaboration et al (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 68:1810\u20131817","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4071-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T19:30:19Z","timestamp":1555097419000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4071-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["4071"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4071-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]},"assertion":[{"value":"14 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"VO-W declares speaker\u2019s fees from Roche, Abbvie, Pfizer, outside the submitted work. Z.\u017b declares no conflicts of interest. EA has received research grants from Roche, Abbott, Pfizer, Bristol-Myers Squibb, Centocor, and Novartis and received honoraria as a speaker for Roche, Novartis, and Pfizer. VCh declares no conflicts of interest. IN has received speaker\u2019s fees from Roche, AbbVie, Pfizer, Bristol-Myers Squibb, and Novartis. GD was an employee of Roche Polska Sp. z o.o. till 30.04.2015 (during the research concept and protocol development, in the time of study conduct, data analysis, and result interpretation). ES declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines and with local requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}